Your Yourlocation: Home > Tiotropium bromide(136310-93-5) is the first LAMA formulation for the treatment of COPD

Tiotropium bromide(136310-93-5) is the first LAMA formulation for COPD treatment and important UPLIFT studies have demonstrated its ability to reduce the annual FEV1 reduction in patients by nearly half. For patients with COPD who underwent pulmonary rehabilitation, the treatment would be better and would often result in a significant reduction in FEV1 in patients who stopped.

As a new LAMA and glycopyrrolate for the treatment of patients with moderate to severe COPD, glybromide has shown significant improvements in the following indicators compared with placebo: patients with pulmonary valvular FEV1 assessment Function, dyspnea score, health status, frequency of exacerbations, and duration of exercise tolerance.

The main deficiencies of the GLOW1 and GLOW2 studies include, as the European Medical Council considers it, that they do not use the most potent clinical criteria to exclude those with asthma; the covert approach to patient grouping is too obvious; and most subjects are medium Degree of COPD patients, but also hindered the relevant data for mild or severe COPD applicability.

Differences in efficacy and safety between glycopyrrolate and tiotropium bromide(136310-93-5) have also been evaluated, and the results indicate that the two drugs are of considerable homogeneity. However, the main drawback of this comparative study is the inability to blindly study tiotropium therapy.

A striking difference between glycopyrrolate and tiotropium is that the onset time of the former is about 3-5 times faster than the latter. This will make the patient earlier to feel the effect of glycopyrrolate, thereby increasing their therapeutic compliance. In fact, compliance is an important consideration in any drug therapy.

For example, a study involving 23,707 patients treated with tiotropium bromide(136310-93-5) inhaled tiotropium bromide(136310-93-5) (fluticasone propionate /salmeterol alone or in combination) showed a decrease in treatment compliance, an increased risk of acute exacerbation, and Its higher rate of medical treatment related. Whether a patient's perception of rapid onset of glycopyrrolate is really associated with improvements in treatment compliance remains to be confirmed by specific studies in this area.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved